Floatz logo

pd1-til

PD-1

Ruijin HospitalCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

6 Active assets in the PD-1 cohort.

Asset / SponsorPhaseRating
Dasatinib
The Affiliated Hospital of Qingdao University
Phase 2CCC
Ruxoprubart
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2CCC
LENVATINIB
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC
f520
Shandong New Time Pharmaceutical Co., LTD
Phase 2CCC
Carboplatin
Shandong New Time Pharmaceutical Co., LTD
Phase 2CCC
Tuvonralimab
Anhui Provincial Hospital
Phase 2CCC
pd-1 knockout engineered t cells
Ruijin Hospital
Phase 1CC

Same molecule, other indications

pd1-til is also rated in:

Tumor Infiltrating LymphocytesDormant
CC
Indicative ·
43 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
39 / 100
View asset →
glioblastomaDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →